Key Takeaways
- A March 5 FDA warning letter flagged Novo Nordisk for not reporting adverse events associated with semaglutide, found in both Ozempic and Wegovy.
- The letter mentioned three fatalities, including a suicide case that the company allegedly didn’t investigate or report on time.
- Novo Nordisk has a 14-day deadline to outline corrective measures to the FDA.
- The pharmaceutical giant maintains that the warning won’t affect manufacturing operations or its investor outlook.
- Shares of NVO have fallen 27% in 2026, currently hovering near $38.32.
It’s been a turbulent year for Novo Nordisk, and recent news from federal regulators has only added to the company’s challenges.
On March 5, the Food and Drug Administration delivered a warning letter to the Copenhagen-based pharmaceutical company, highlighting “serious violations” in its adverse event reporting practices for semaglutide, the key compound in its blockbuster medications Ozempic and Wegovy.
These compliance failures came to light when FDA inspectors visited a Novo Nordisk site in New Jersey during the previous year.
The warning letter specifically referenced three fatalities—two deaths and one suicide—with regulators pointing out that the suicide incident wasn’t properly investigated or submitted to authorities within mandatory timeframes.
Importantly, the FDA clarified it isn’t asserting that these medications directly caused the deaths. Instead, the agency’s concern centers on procedural lapses in the reporting system rather than establishing causation.
“FDA relies on the complete, accurate, and timely submission of ADEs to monitor a product’s safety profile,” the regulatory body stated, using the abbreviation for adverse drug events.
Novo Nordisk now has 14 days to inform the FDA about remedial actions it intends to implement to avoid similar infractions going forward.
In a public statement, the pharmaceutical company indicated it has been working “diligently” to resolve the FDA’s issues. The firm confirmed submitting an original response along with seven subsequent updates to regulators.
The company also stated that the flagged cases “have been evaluated” and are now “processed and reported appropriately.” Notably, Novo didn’t dispute its earlier reporting failures.
Mounting Regulatory Concerns
This isn’t Novo’s initial encounter with FDA enforcement actions in recent months. Back in December, federal regulators sent another warning letter to the company’s Bloomington, Indiana manufacturing plant concerning Good Manufacturing Practice violations.
Additionally, the FDA sent two letters in February criticizing marketing materials for Ozempic and Wegovy for containing “false or misleading claims” regarding effectiveness and safety information. A February 26 correspondence specifically took issue with Novo positioning Ozempic as a better option than rival treatments.
In its press statement, Novo acknowledged the recurring issues, commenting simply: “We work in a highly regulated space.”
The pharmaceutical manufacturer insists the most recent warning won’t disrupt production schedules or alter the financial projections it has communicated to shareholders.
Shares Decline 27% in 2026
NVO has experienced significant losses throughout 2026. Trading around $38.32, the stock has plummeted 27% year to date, marking a substantial retreat from previous peak levels.
The downturn stems from several factors—intensifying regulatory oversight combined with fierce competition from Eli Lilly, whose competing GLP-1 medication Mounjaro has gained market share, have both dampened investor confidence.
Political factors have compounded the challenges. Health Secretary RFK Jr. has openly criticized Ozempic as excessively expensive, and previously prevented a Biden administration initiative that would have extended Medicare coverage for GLP-1 medications to approximately 7 million beneficiaries.
As of Tuesday afternoon, the stock was changing hands at $38.32.
